A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Clinical trial NCT07186842 · RECRUITING

Trial details

NCT number: NCT07186842
Sponsor: BioNTech SE
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Cancers

Start date: 2025-11-18
Primary completion: 2030-05-01
Enrollment: 245

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.